好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neuroimaging Correlates of Gait Abnormalities in Progressive Supranuclear Palsy
Movement Disorders
P1 - Poster Session 1 (9:00 AM-5:00 PM)
248

To examine the associations between neuroimaging and gait and balance abnormalities in progressive supranuclear palsy (PSP).

PSP is a neurodegenerative disorder characterized primarily by tau inclusions and neurodegeneration in the midbrain, basal ganglia, thalamus, premotor and frontal cortex. While PSP can present with a variety of clinical syndromes, gait impairments and postural instability are common early features.

MRI atrophy, white matter tracts degeneration from diffusion tensor imaging, flortaucipir-PET uptake as well as laboratory-based gait and balance measurements were assessed in 19 PSP patients. Associations between these quantities were assessed with univariate and multivariate analyses.

Principal component analysis on gait variables identified velocity, stride length, length of gait phases and dynamic stability as the main contributors to the first component, which was associated with disruption of the posterior thalamic radiation, external capsule, superior cerebellar peduncle, superior fronto-occipital fasciculus, corpus callosum and sagittal stratum, atrophy in frontal and precentral regions and flortaucipir-PET uptake in the precentral gyrus. The main contributor to the second principal component was cadence, which was unexpectedly higher in patients presenting higher mean diffusivity, suggesting compensatory gait strategies in PSP. Postural imbalance was the main contributor to the third principal component, which was mainly related to flortaucipir-PET uptake in the left paracentral lobule and supplementary motor area and disruption of various white matter tracts. Spearman’s correlations on gait and imaging quantities revealed differences between the PSP Richardson’s syndrome sub-group (n=13) and the other PSP variants. A partial least square model identified flortaucipir-PET uptake in midbrain, basal ganglia and thalamus as the main correlate of speed and dynamic component of gait in PSP.

Although causality cannot be established, our study sheds light on neurodegeneration of brain regions and white matter tracts that underlies gait and balance impairment in PSP, suggesting that there might be variation across PSP variants.

Authors/Disclosures
Irene Sintini, PhD (Mayo Clinic)
PRESENTER
Dr. Sintini has nothing to disclose.
No disclosure on file
Hugo Botha, MD (Mayo School of Graduate Medical 好色先生, Rochester) Dr. Botha has received research support from NIH. An immediate family member of Dr. Botha has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH.
No disclosure on file
Matthew Senjem (Mayo Clinic) Matthew Senjem has received stock or an ownership interest from Align Technology, Inc.. Matthew Senjem has received stock or an ownership interest from Inovio Biomedical Corp.. Matthew Senjem has received stock or an ownership interest from Johnson & Johnson. Matthew Senjem has received stock or an ownership interest from Mesa Laboratories, Inc.. Matthew Senjem has received stock or an ownership interest from Nvidia Inc.. Matthew Senjem has received stock or an ownership interest from LHC Group, Inc.. Matthew Senjem has received stock or an ownership interest from Natus Medical Incorporated. Matthew Senjem has received stock or an ownership interest from Varex Imaging Corporation. Matthew Senjem has received personal compensation in the range of $100,000-$499,999 for serving as a IT Technical Specialist II with Mayo Clinic.
Robert I. Reid No disclosure on file
Christopher Schwarz The institution of Christopher Schwarz has received research support from NIH.
Clifford R. Jack, Jr., MD (Mayo Clinic) The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.
Val J. Lowe, MD (Mayo Clinic) Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals.
Keith A. Josephs, Jr., MD, FAAN (Mayo Clinic) Dr. Josephs has nothing to disclose.
Jennifer Whitwell, PhD (Mayo Clinic) The institution of Dr. Whitwell has received research support from NIH.
Farwa Ali, MD (Mayo Clinic) Dr. Ali has nothing to disclose.